ANDA 212423, held by Quagen. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 212423 (Cyproheptadine Hydrochloride), held by Quagen, was first approved by FDA on May 22, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 22, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyproheptadine Hydrochloride2MG/5ML · syrup;oral | Cyproheptadine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters